Epidemiology of liver cancer in Kazakhstan: data from the Unified National Electronic Health System, 2014–2023

Ablayeva A. Syssoyev D. Akhmedullin R. Beyembetova A. Abdukhakimova D. Aimyshev T. Arupzhanov I. Zhakhina G. Biniyazova A. Seyil T. Igissin N. Semenova Y. Gaipov A.
August 2025 Public Library of Science

PLOS ONE
2025 #20 Issue 8 August

Liver cancer is the third-deadliest cancer globally, significantly affecting the Asian population, which accounts for 70% of cases. Despite these numbers, the burden of liver cancer in Central Asia, including Kazakhstan, remains underexplored. This paper reviews the epidemiology of liver cancer in Kazakhstan by analyzing large-scale administrative data from the national registry. Methods The study cohort included 10,455 patients diagnosed with liver neoplasms (C22.0-C22.9, D13.4) from 2014 to 2023, using the International Classification of Diseases, 10th Revision (ICD-10). Age-standardized incidence, mortality, and prevalence rates per 100,000 population were calculated. Cox regression analysis estimated hazard ratios across social-demographic and medical predictors. Results Over the decade, age-standardized incidence rates decreased from 5.55 to 5.40 per 100,000, while mortality rates rose from 3.75 to 4.75 per 100,000. A downward trend appeared between 2017–2019 but gradually reversed post-2020. Prevalence rates steadily increased from 1.30 to 7.32 per 100,000. The cohort’s mean age was 63.2±0.1 years, with most cases diagnosed as stage III hepatocellular carcinoma. West Kazakhstan, East Kazakhstan, and Pavlodar were the most burdened regions. Liver cirrhosis history predicted worse survival (Hazard Ratio, HR=1.14; 95% CI 1.06–1.22), while primary hypertension showed a protective effect (HR=0.82; 95% CI 0.78–0.86). Conclusions Liver cancer morbidity and mortality rates have risen in Kazakhstan over the past decade, with a slight decrease during the early COVID-19 pandemic. Patients are mostly diagnosed with stage III hepatocellular carcinoma. West Kazakhstan, East Kazakhstan, and Pavlodar are the most affected regions, requiring better management of high-risk groups. Poor survival was linked to liver cirrhosis. Further research on the role of rising metabolic liver diseases and treatment options in Kazakhstan is needed to better predict liver cancer prognosis.

Text of the article Перейти на текст статьи

Department of Medicine, Nazarbayev University School of Medicine, Astana, Kazakhstan
Life Sciences and Health Research Institute, Ualikhanov University, Kokshetau, Kazakhstan
Clinical Academic Department of Internal Medicine, Corporate Fund “University Medical Center”, Astana, Kazakhstan

Department of Medicine
Life Sciences and Health Research Institute
Clinical Academic Department of Internal Medicine

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026